|
Name |
Company |
Description |
|
Phase III |
||
|
Aplidin® (plitidepsin) |
PharmaMar, SA |
Marine-derived antitumor agent being evaluated in combination with dexamethasone (dex) LEARN MORE |
|
Carfilzomib (PR-171) |
Onyx Pharmaceuticals |
Proteasome inhibitor being evaluated alone, as part of combination therapy (including with Revlimid-dex in a phase III study), and as frontline or maintenance therapy LEARN MORE |
|
Denosumab (AMG 162) |
Amgen |
Human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits bone destruction; under review by the FDA for use in myeloma; approved as Xgeva® for use in bone disease in solid tumors and as Prolia® for osteoporosis |
|
Elotuzumab (HuLuc63; humanized anti-CS1 monoclonal antibody) |
Bristol-Myers Squibb/Abbott |
Monoclonal antibody that binds to CS1, a cell surface protein that is highly expressed on myeloma cells; being evaluated in combination with Revlimid-dex in phase III studies in relapsed and previously untreated patients, as well as alone and with other agents LEARN MORE |
|
Panobinostat (LBH589) |
Novartis |
Deacetylase (DAC) inhibitor; being evaluated in combination with other agents, including Velcade-dex in a phase III study LEARN MORE |
|
Perifosine (KRX-0401, D-21266) |
Keryx Biopharmaceuticals, Inc. |
Oral anticancer agent that inhibits cell growth and promotes apoptosis; being evaluated alone and combination with other agents, including Velcade-dex in a phase III study LEARN MORE |
|
Pomalidomide (CC-4047) |
Celgene Corporation |
Type of IMiD™ (immunomodulatory drug) being evaluated alone and in combination with other agents, including a phase III study in combination with dexamethasone LEARN MORE |
|
Siltuximab (CNTO 328) |
Janssen Biotech, Inc. |
Anti-interleukin-6 monoclonal antibody being evaluated alone and in combination with other agents, including Velcade-dex in a phase III study LEARN MORE |
|
Zolinza® (vorinostat, SAHA [suberoylanilide hydroxamic acid]) |
Merck |
Histone deacetylase (HDAC) inhibitor, FDA-approved for cutaneous T-cell lymphoma, that has shown activity in relapsed and refractory myeloma; being evaluated in combination with Velcade in a phase III study, as well as with other agents LEARN MORE |
|
Phase II |
||
|
Afinitor® (everolimus, RAD001, Certican®) |
Novartis |
mTor inhibitor, FDA-approved for renal cell and pancreatic neuroendocrine tumors, being evaluated alone and in combination with other agents; known as Certican outside the US, where it is used in preventing transplant rejection |
|
Aflibercept (VEGF Trap) |
Regeneron/sanofi-aventis |
Anti-angiogenic fusion protein that binds VEGF |
|
AT7519 (AT7519M) |
Astex Therapeutics |
Cyclin-dependent kinase (CDK) inhibitor being evaluated alone and combination with Velcade |
|
ARRY-520 |
Array BioPharma |
Agent that inhibits kinesin spindle protein (KSP); being evaluated alone and in combination in relapsed and refractory myeloma |
|
Bexxar® (iodine I 131 tositumomab) |
GlaxoSmithKline |
FDA-approved radiolabeled monoclonal antibody directed against CD20, a marker found on B cells and 20% to 25% of myeloma cells |
|
CEP-18770 |
Cephalon |
Proteasome inhibitor; being investigated alone and in combination with Revlimid |
|
Dinaciclib (SCH 727965, MK-7965) |
Merck/Ligand Pharmaceuticals |
Cyclin-dependent kinase (CDK) inhibitor |
|
Dovitinib (TKI258) |
Novartis |
Oral novel agent (FGFR3 inhibitor) that displays antitumor activity and inhibits angiogenesis |
|
Imetelstat (GRN163L) |
Geron Corporation |
Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth; being evaluated alone and in combination with Velcade |
|
IPH21 (IPH2101, IPH2102) |
Innate Pharma/Bristol-Myers Squibb |
Monoclonal antibody (anti-KIR) that enhances killing of myeloma cells by natural killer (NK) cells; being evaluated alone and in combination with other agents, as well as in smoldering myeloma and in patients in stable partial response after frontline therapy |
|
Istodax® (romidepsin) |
Celgene Corporation |
Histone deacetylase (HDAC) inhibitor approved for use in a specific type of lymphoma; being evaluated in combination with Velcade |
|
KW-2478 |
Kyowa Hakko Kirin Co., Ltd. |
Heat-shock protein (HSP) 90 inhibitor being evaluated in combination with Velcade |
|
Milatuzumab (IMMU-110) and milatuzumab-doxorubicin conjugate (hLL1-DOX) |
Immunomedics |
Humanized monoclonal antibody directed against the CD74 protein found on B cells and myeloma cells; being evaluated as a therapeutic monoclonal antibody and an antibody-drug conjugate |
|
MLN8237 |
Millennium: The Takeda Oncology Company |
Novel agent (Aurora A kinase inhibitor) being evaluated in combination with Velcade |
|
MLN9708 |
Millennium: The Takeda Oncology Company |
Oral second-generation proteasome inhibitor; being evaluated in combination with several other agents in newly diagnosed disease |
|
Nexavar® (sorafenib) |
Bayer/Onyx Pharmaceuticals |
Multi-kinase inhibitor FDA-approved for use in renal cell carcinoma that inhibits cell growth and angiogenesis; being evaluated alone and in combination with other agents |
|
PD 0332991 |
Pfizer |
Kinase inhibitor being evaluated in combination with Velcade and dexamethasone |
|
Rituxan® (rituximab) |
Genentech/Biogen Idec. |
Monoclonal antibody FDA-approved for use in non-Hodgkin lymphoma that targets the CD20 marker found on B cells and 20% to 35% of myeloma cells |
|
RO4929097 |
Hoffmann-La Roche, Inc. |
Gamma-secretase inhibitor being evaluated in patients who have measurable disease following autologous stem cell transplantation |
|
Ruxolitinib (INCB018424) |
Incyte Corporation |
Oral novel agent (Janus kinase [JAK] inhibitor) |
|
Selumetinib (AZD6244, ARRY-142886) |
AstraZeneca/Array BioPharma Inc. |
Protein kinase (MEK) inhibitor |
|
Sprycel® (dasatinib) |
Bristol-Myers Squibb |
Kinase inhibitor FDA-approved for use in chronic myelogenous leukemia; being evaluated in combination with Velcade or Revlimid-dex |
|
Torisel® (temsirolimus, CCI-779) |
Wyeth |
mTOR inhibitor FDA-approved for use in renal cell carcinoma; being evaluated alone and in combination with other agents |
|
Treanda® (bendamustine hydrochloride; known as Ribomustin® in Germany) |
Cephalon |
Alkylating agent FDA-approved for use in treating leukemia and lymphoma; approved in Germany for use in myeloma; being evaluated as part of various combination therapies for use in newly diagnosed and relapsed and/or refractory disease LEARN MORE |
|
Vidaza® (azacitidine) |
Celgene Corporation |
Cytotoxic drug FDA-approved for the treatment of myelodysplastic syndromes (MDS) being evaluated alone and in combination with other agents |
|
Phase I |
||
|
ACXY-1215 |
Acetylon Pharmaceuticals, Inc. |
Selective histone deacetylase (HDAC) inhibitor |
|
Amrubicin |
Celgene Corporation |
Chemotherapy drug approved in Japan for small-cell lung cancer; being evaluated in combination with Revlimid-dex |
|
AUY922 |
Novartis |
Heat shock protein (HSP90) inhibitor being tested alone and in combination with other Velcade, with or without dexamethasone |
|
BI-505 |
BioInvent International AB |
Monoclonal antibody directed against ICAM-1, a protein that enables immune cells to migrate from the blood into tissues |
|
BKT140 |
Biokine Therapeutics |
Novel agent that can enhance stem cell mobilization and also causes myeloma cell death |
|
BMS-833923 |
Bristol-Myers Squibb/Exelixis |
Oral anticancer agent being evaluated alone and in combination with Revlimid-dex or Velcade |
|
BT062 |
Biotest AG |
Anti-CD138 monoclonal antibody/cytotoxic agent compound that has demonstrated activity in early testing |
|
CC-223 |
Celgene Corporation |
Dual mTOR inhibitor |
|
CX-4945 |
Cylene Pharmaceuticals |
Oral protein kinase (CK2) inhibitor |
|
Daratumumab (HuMax-CD38) |
Genmab |
Human monoclonal antibody that targets the CD38 molecule, which is highly expressed on the surface of myeloma cells |
|
Folotyn® (pralatrexate) |
Allos Therapeutics |
Chemotherapy drug approved for use in peripheral T-cell lymphoma that is being evaluated in combination with Velcade |
|
Ganetespib (STA-9090) |
Synta Pharmaceuticals |
Synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90); being evaluated in collaboration with the MMRF |
|
GDC-0449 |
Genentech |
Synthetic Hedgehog pathway inhibitor |
|
INK128 |
Intellikine |
Oral kinase inhibitor |
|
Lorvotuzumab mertansine (IMGN901, BB-10901) |
ImmunoGen |
Monoclonal antibody directed against the CD56 marker found on myeloma cells, coupled with a cancer drug; being evaluated alone and in combination with Revlimid-dex |
|
LY2127399 |
Lilly |
Antibody directed against a protein that activates B cells being tested in combination with Velcade |
|
MFGR1877S |
Genentech |
Monoclonal antibody (anti-FGFR3) being evaluated in patients with t(4;14)-positive myeloma |
|
MLN4924 |
Millennium: The Takeda Oncology Company |
Novel agent (inhibitor of Nedd8 activating enzyme) |
|
MOR03087 |
MorphoSys AG |
Human anti CD38 antibody |
|
Noscapine (CB3304) |
Janssen Biotech, Inc. |
Cough suppressant with anti-cancer microtubule inhibition properties |
|
NPI-0052 |
Nereus |
Novel proteasome inhibitor that has shown promising early safety data LEARN MORE |
|
Oncolytic measles virus (MV-NIS) |
Mayo Clinic |
Genetically engineered measles virus being administered with or without cyclophosphamide |
|
Veliparib (ABT888) |
Abbott Laboratories |
PARP1 and PARP2 inhibitor |
|
Zarnestra™ (R115777, tipifarnib,FTI) |
Ortho Biotech Oncology Research & Development |
Farnesyl transferase inhibitor; activity seen in combination with Velcade in a phase I trial |
 |
|
|
|
Corporate Supporters | Terms of Use | Privacy Policy Copyright © 2012 Multiple Myeloma Research Foundation |
